Imaging With a PET Agent for Detection of Cancers of the Head and Neck

• Status: Active, not recruiting
• Trial end date: 2022-08-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to test the safety of a study drug called PARPi-FL. This drug has been tested in animals but not yet in people. The purpose of this study is to test if a PARPi-FL scan can be used to take pictures of head and neck cancer. The usual approach to imaging this cancer includes several different imaging scans, including x-rays, CT (computed tomography), MRI (magnetic resonance imaging), and PET (positron emission tomography). These tests take pictures of the cancer.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Memorial Sloan Kettering Cancer Center

Criteria

Inclusion Criteria:

• Age ≥18 years

• ECOG performance status 0 or 1

• Biopsy (histologically or cytologically) proven Squamos Cell Carcinoma

• Oral cavity, oropharynx, or nasopharynx primary site

• At least one tumor lesion on standard of care imaging with a minimum diameter of at least 1.5 cm

• Scheduled to undergo treatment at MSKCC

• Willingness to sign informed consent

Exclusion Criteria:

• Significantly impaired organ function that may interfere with the excretion and metabolism of the imaging agent. Specifically, patients will be excluded if they meet the following criteria:

• Hematologic

o Platelets <75K/mcL

• Hepatic

• Bilirubin >2.0 x ULN (institutional upper limits of normal)

• AST/ALT >2.5 x ULN

• Renal

o Creatinine > 2.0 x ULN

• Claustrophobia interfering with PET/CT imaging

• Known allergy to PEG300

• Pregnancy or breastfeeding